Lymphoproliferative Disorders [clinicaltrials_resource:3339fa7fdc241ee58ccf94dc298abfc5]
A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes [clinicaltrials:NCT00001438]Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders [clinicaltrials:NCT00002153]Clofarabine in Chronic Lymphocytic Leukemia [clinicaltrials:NCT00028418]Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H [clinicaltrials:NCT00048412]Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs). [clinicaltrials:NCT00058604]Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant [clinicaltrials:NCT00063648]Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma [clinicaltrials:NCT00068146]Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease [clinicaltrials:NCT00123942]Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies [clinicaltrials:NCT00131014]clinicaltrials:NCT00345345clinicaltrials:NCT00579111Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders [clinicaltrials:NCT00968461]Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders [clinicaltrials:NCT00992732]Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC) [clinicaltrials:NCT01186224]Pathogenesis of Hematologic Malignancies [clinicaltrials:NCT01728402]clinicaltrials:NCT02182986clinicaltrials:NCT02505789
condition [clinicaltrials_vocabulary:condition]
Study of Autoimmune Lymphoproliferative Syndrome (ALPS) [clinicaltrials:NCT00001350]clinicaltrials:NCT00001379A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes [clinicaltrials:NCT00001438]Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine [clinicaltrials:NCT00001533]Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders [clinicaltrials:NCT00002153]clinicaltrials:NCT00002663Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants [clinicaltrials:NCT00002956]Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression Therapy [clinicaltrials:NCT00003716]Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation [clinicaltrials:NCT00005606]Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies [clinicaltrials:NCT00006054]Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders [clinicaltrials:NCT00006056]Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer [clinicaltrials:NCT00006251]Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus [clinicaltrials:NCT00006340]PS-341 in Treating Patients With Advanced Cancer [clinicaltrials:NCT00006362]Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome [clinicaltrials:NCT00013689]Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies [clinicaltrials:NCT00014235]clinicaltrials:NCT00023764Clofarabine in Chronic Lymphocytic Leukemia [clinicaltrials:NCT00028418]Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation [clinicaltrials:NCT00033475]Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma [clinicaltrials:NCT00036855]Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer [clinicaltrials:NCT00039676]Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H [clinicaltrials:NCT00048412]clinicaltrials:NCT00049504Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders [clinicaltrials:NCT00052572]clinicaltrials:NCT00053053Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma [clinicaltrials:NCT00058227]clinicaltrials:NCT00058331Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs). [clinicaltrials:NCT00058604]Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant [clinicaltrials:NCT00063648]Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder [clinicaltrials:NCT00064246]Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome [clinicaltrials:NCT00065390]clinicaltrials:NCT00066469Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma [clinicaltrials:NCT00068146]clinicaltrials:NCT00070382Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant [clinicaltrials:NCT00078858]clinicaltrials:NCT00087009Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer [clinicaltrials:NCT00089011]clinicaltrials:NCT00092222clinicaltrials:NCT00093704Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer [clinicaltrials:NCT00112593]
condition browse [clinicaltrials_vocabulary:condition-browse]
Study of Autoimmune Lymphoproliferative Syndrome (ALPS) [clinicaltrials:NCT00001350]clinicaltrials:NCT00001379A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes [clinicaltrials:NCT00001438]Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine [clinicaltrials:NCT00001533]Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders [clinicaltrials:NCT00002153]clinicaltrials:NCT00002663Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants [clinicaltrials:NCT00002956]Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression Therapy [clinicaltrials:NCT00003716]Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation [clinicaltrials:NCT00005606]Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies [clinicaltrials:NCT00006054]Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders [clinicaltrials:NCT00006056]Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer [clinicaltrials:NCT00006251]Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus [clinicaltrials:NCT00006340]PS-341 in Treating Patients With Advanced Cancer [clinicaltrials:NCT00006362]Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome [clinicaltrials:NCT00013689]Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies [clinicaltrials:NCT00014235]clinicaltrials:NCT00023764Clofarabine in Chronic Lymphocytic Leukemia [clinicaltrials:NCT00028418]Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation [clinicaltrials:NCT00033475]Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma [clinicaltrials:NCT00036855]Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer [clinicaltrials:NCT00039676]Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H [clinicaltrials:NCT00048412]clinicaltrials:NCT00049504Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders [clinicaltrials:NCT00052572]clinicaltrials:NCT00053053Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma [clinicaltrials:NCT00058227]clinicaltrials:NCT00058331Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs). [clinicaltrials:NCT00058604]Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant [clinicaltrials:NCT00063648]Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder [clinicaltrials:NCT00064246]Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome [clinicaltrials:NCT00065390]clinicaltrials:NCT00066469Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma [clinicaltrials:NCT00068146]clinicaltrials:NCT00070382Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant [clinicaltrials:NCT00078858]clinicaltrials:NCT00087009Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer [clinicaltrials:NCT00089011]clinicaltrials:NCT00092222clinicaltrials:NCT00093704Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer [clinicaltrials:NCT00112593]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
Lymphoproliferative Disorders [clinicaltrials_resource:3339fa7fdc241ee58ccf94dc298abfc5]
Bio2RDF identifier
3339fa7fdc241ee58ccf94dc298abfc5
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:3339fa7fdc241ee58ccf94dc298abfc5
identifier
clinicaltrials_resource:3339fa7fdc241ee58ccf94dc298abfc5
title
Lymphoproliferative Disorders
@en
type
label
Lymphoproliferative Disorders [clinicaltrials_resource:3339fa7fdc241ee58ccf94dc298abfc5]
@en
Lymphoproliferative Disorders